Meronym, 0,5 g 10 pcs

Infectious diseases, Skin infections, Lung infections (pneumonia), Urinary tract infections, Intestinal infections, Respiratory tract infections

Meronem^® is indicated for the treatment in children (over 3 months) and adults for the following infectious and inflammatory diseases caused by one or more pathogens sensitive to meropenem:

• pneumonias, including nosocomial pneumonias;
• infections of the urinary system;
• infections of the abdomen;
• infections of the skin and its structures;
• meningitis;
• septicemia.

Empirical therapy in adult patients with suspected infection with symptoms of febrile neutropenia in monotherapy or in combination with antiviral or antifungal agents.

The efficacy of Meronem^® has been proven both in monotherapy and in combination with other antimicrobials in the treatment of polymicrobial infections.

Active ingredient

Composition

Active ingredient:

meropenem trihydrate;

Associates:

sodium carbonate (anhydrous) – 208 mg

How to take, the dosage

The drug Meronem is intended for intravenous administration.

The dosage is 20-40 mg/kg by weight every 8 hours, with a maximum dose of 1-2 g every 8 hours.

Interaction

Special Instructions

There is no experience with the use of the drug in pediatric practice in patients with neutropenia or with primary or secondary immunodeficiency.

As with other antibiotics, regular sensitivity testing is recommended when using meropenem in monotherapy in critically ill patients with or suspected of having a lower respiratory tract infection caused by Pseudomonas aeruginosa.

In rare cases when using Meronem®, as with virtually all antibiotics, the development of pseudomembranous colitis is observed, which may vary in severity from mild to life-threatening forms. It is important to remember about the possibility of development of pseudomembranous colitis when diarrhea occurs against the background of Meronem® use.

There are clinical and laboratory signs of cross-allergic reactions between other carbapenems and beta-lactam antibiotics, penicillins and cephalosporins. There have been rare reports of hypersensitivity reactions (including fatal outcome) when using Meronem®, as well as other beta-lactam antibiotics (see section “Side effects”).

Before initiating therapy with meropenem, the patient should be carefully questioned, paying particular attention to any history of hypersensitivity reactions to beta-lactam antibiotics. Meronem® should be used with caution in patients with a history of such events. If an allergic reaction to meropenem has occurred, the drug should be discontinued and appropriate measures taken.

The use of Meronem® in patients with liver disease must be monitored closely for transaminase activity and bilirubin concentrations.

As with other antibiotics, overgrowth of insensitive microorganisms is possible, so continuous patient monitoring is necessary.

The prevalence of acquired antibiotic resistance of different pathogens may vary by region and time, and up-to-date information on the resistance of common pathogens in a particular region is desirable, especially when treating severe infections. If resistance is such that the efficacy of the drug against at least some infections becomes questionable, an expert should be consulted.

The co-administration of Meronem® and valproic acid drugs is not recommended.

The use of the drug in infections caused by methicillin-resistant Staphylococcus aureus is not recommended.

Impact on the ability to drive and operate machinery. No studies have been performed on the effect of Meronem® on the ability to drive a car and operate other machinery. However, it should be taken into account that headache, paresthesia, and seizures may occur when taking Meronem®.

Contraindications

With caution: concomitant use with potentially nephrotoxic drugs; patients with gastrointestinal complaints (diarrhea), especially those with colitis.

Side effects

Blood system: frequently – thrombocytosis; infrequently – eosinophilia, thrombocytopenia; rarely – leukopenia, neutropenia, agranulocytosis; very rarely – hemolytic anemia.

Nervous system: infrequent – headache, paresthesia, syncope, hallucinations, depression, anxiety, increased excitability, insomnia; rarely – seizures.

Gastrointestinal tract: frequently – nausea, vomiting, diarrhea, increased liver transaminase activity, ALP, LDH, and concentration of bilirubin in serum; infrequently – constipation, cholestatic hepatitis; very rarely – pseudomembranous colitis.

The skin and subcutaneous tissue: infrequent – rash, urticaria, itching, very rare – erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.

Immune system: very rarely – angioedema, manifestations of anaphylaxis.

CRC: infrequent – heart failure, cardiac arrest, tachycardia, bradycardia, myocardial infarction, decreased or increased BP, pulmonary artery branch thromboembolism.

Kidney and urinary tract: infrequent – increased blood creatinine concentration, increased blood urea concentration.

Respiratory tract: infrequent – dyspnea.

Others: frequent – local reactions (inflammation, thrombophlebitis, pain at the injection site); rarely – vaginal candidiasis and oral candidiasis.

Overdose

Pregnancy use

Pregnancy

The safety of Meronem® in women during pregnancy has not been studied. Animal studies have not shown any adverse effects on the developing fetus.

Meronem® should not be used during pregnancy unless the potential benefit to the mother from its use exceeds the possible risk to the fetus. In each case, the drug should be used under the close supervision of a physician.

Lactation

Meropenem is detectable in animal breast milk at very low concentrations. Meropenem® should not be used during breastfeeding unless the potential benefit to the mother from using the drug exceeds the possible risk to the baby. After assessing the benefit to the mother, the decision should be made to discontinue breastfeeding or to discontinue Meronem®.